ERS Genomics grants Transomic access to CRISPR/Cas9 portfolio
In a non-exclusive licensing agreement, ERS Genomics has granted Transomic Technologies access to the foundational ERS CRISPR/Cas9 patent portfolio.
If you are not happy with the results below please do another search
In a non-exclusive licensing agreement, ERS Genomics has granted Transomic Technologies access to the foundational ERS CRISPR/Cas9 patent portfolio.